Duchesnay and PeriPharm Call for Regulatory Reform as Canadian Women Wait 3+ Years for Health Innovations

Key Takeaways

• Canadian women wait more than three years to access new health innovations according to joint Duchesnay-PeriPharm study
• Research published in Journal of Obstetrics and Gynaecology Canada identifies significant gaps in women’s healthcare access
• Companies advocate for updated regulatory and reimbursement policies to accelerate patient access to treatments

---

Canadian Women Face Extended Wait Times for Health Innovations

Duchesnay, a leading Canadian specialty pharmaceutical company, and PeriPharm have published groundbreaking research highlighting critical delays in women’s healthcare access across Canada. The joint study, featured in the Journal of Obstetrics and Gynaecology Canada, documents that Canadian women experience wait times exceeding three years before gaining access to new health innovations.

IntelligenceRegulatory Impact▾

NMPA, PMDA, and TGA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Study Reveals Systemic Healthcare Access Issues

The collaborative research between Duchesnay, a member of Duchesnay Pharmaceutical Group (DPG) with decades of women’s health expertise, and PeriPharm, a specialized Canadian healthcare company, exposes significant structural barriers within Canada’s healthcare system. These delays particularly impact women seeking access to cutting-edge treatments and medical innovations.

The findings suggest that current regulatory frameworks and reimbursement policies create substantial bottlenecks, preventing timely patient access to potentially life-changing therapies. This research comes at a critical time when healthcare accessibility remains a top priority for Canadian policymakers and healthcare providers.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Industry Leaders Push for Policy Reform

Both companies are leveraging their research findings to advocate for comprehensive updates to existing regulatory and reimbursement structures. The proposed changes aim to streamline approval processes while maintaining safety standards, ultimately reducing the time between innovation development and patient access.

The pharmaceutical industry has increasingly focused on women’s health as an underserved market segment, making these access delays particularly concerning for patient outcomes and healthcare equity. The study’s publication in a peer-reviewed medical journal adds scientific credibility to ongoing policy discussions about healthcare reform in Canada.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Market Implications and Future Outlook

This research could influence future regulatory decisions and healthcare policy development across Canada. The collaboration between established pharmaceutical companies like Duchesnay and specialized firms like PeriPharm demonstrates industry-wide commitment to addressing systemic healthcare access challenges through evidence-based advocacy.

---

Frequently Asked Questions

What does this mean for Canadian women seeking new treatments?

The study confirms that Canadian women currently face wait times of over three years to access new health innovations, but the research may help accelerate policy reforms to reduce these delays.

When might regulatory changes be implemented?

While no specific timeline has been announced, the publication of this peer-reviewed research provides evidence that policymakers can use to inform future regulatory and reimbursement policy updates.

How does Canada’s access timeline compare to other countries?

The study focuses specifically on Canadian access gaps, though the three-year wait time suggests significant room for improvement compared to more streamlined regulatory systems in other developed nations.

Related coverage

• Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context
• PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open
• Cell and Gene Therapy Approvals in China: Latest Regulatory Updates